MannKind (NASDAQ: MNKD) reported Q2 EPS of ($0.07), $0.01 better than the analyst estimate of ($0.08).

Cash and cash equivalents were $107.2 million at June 30, 2015, compared to $120.8 million in the first quarter of 2015. During the second quarter of 2015, we received $6.7 million in proceeds from warrant and option exercises, $5.5 million in payments from Sanofi for product shipments, and $2.1 million in proceeds from our at-the-market sales facility. Currently, $30.1 million remains available to borrow under our amended loan arrangement with The Mann Group.

For earnings history and earnings-related data on MannKind (MNKD) click here.